Our understanding of the molecular mechanisms underlying cancer development and
evolution have evolved rapidly over recent years, and the variation from one patient to …

About 20% of breast and gastric cancers and 3% of colorectal carcinomas overexpress the
human epidermal growth factor receptor 2 (HER2) and are sensitive to HER2-directed …

Simple Summary Cancer cells are dependent on normal cells for their survival and
functionality because they can use nanoscale tubes to steal the mitochondria from immune …

Introduction Radiotherapy is a mainstay of cancer treatment. Clinical studies revealed a
heterogenous response to radiotherapy, from a complete response to even disease …

Neoadjuvant therapy is commonly used in patients with locally advanced or inoperable
breast cancer (BC). Neoadjuvant chemotherapy (NACT) represents an established …

Purpose: In JACOB trial, pertuzumab added to trastuzumab-chemotherapy did not
significantly improve survival of patients with HER2-positive metastatic gastric cancer …

Background: Advances in cancer medicines have resulted in tangible health impacts, but the
magnitude of benefits of approved cancer medicines could vary greatly. Health Technology …

Purpose For second ipsilateral breast tumor event (2nd IBTE), second conservative
treatment (2nd CT) combining lumpectomy plus accelerated partial breast reirradiation …

Circulating tumor DNA (ctDNA) analysis can identify patients with residual disease before it
is clinically or radiologically evident. Minimal residual disease (MRD) is an advancing area …

Radiotherapy is a mainstay of cancer treatment. The clinical response to radiotherapy is
heterogeneous, from a complete response to early progression. Recent studies have …